Crunch Time For Protection Of New Therapeutic Uses In Europe
EU’s Top Court Given Two Choices On Award Of SPCs
Executive Summary
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.
You may also be interested in...
EU: No SPCs For New Uses OF Existing Drugs
A judgment by the Court of Justice of the EU could offer new opportunities for generics firms but is bad news for innovators seeking supplementary protection certificates to protect new indications for their products.
EU: No SPCs For New Uses OF Existing Drugs
A judgment by the Court of Justice of the EU is bad news for innovators seeking supplementary protection certificates to protect new indications for their products, but it could offer new opportunities for generic firms.
French Court Wants EU Clarity On SPCs For New Uses
A second referral has been made to the Court of Justice of the EU on the tricky question of whether a new formulation or use of an authorized medicine can be granted its own supplementary protection certificate.